Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer
Authors:
- 1 March 2002
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 234 (1-2) , 129-138
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The cellular delivery of antisense oligonucleotides and ribozymesDrug Discovery Today, 2001
- The delivery of antisense therapeuticsAdvanced Drug Delivery Reviews, 2000
- Antisense down‐regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5‐FUdR, 5‐FU and Tomudex in HeLa cellsBritish Journal of Pharmacology, 1999
- The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymersCancer, 1999
- Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheresInternational Journal of Pharmaceutics, 1997
- In vivo studies with antisense oligonucleotidesTrends in Pharmacological Sciences, 1997
- Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivoBritish Journal of Cancer, 1996
- In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil prepared by a solvent evaporation methodInternational Journal of Pharmaceutics, 1996
- Polyalkylcyanoacrylate Nanoparticles as Polymeric Carriers for Antisense OligonucleotidesPharmaceutical Research, 1992
- An update on the biochemistry of 5-fluorouracilCancer Treatment Reviews, 1981